Kenvue Inc. (NYSE:KVUE) Shares Sold by Northeast Investment Management

Northeast Investment Management reduced its position in shares of Kenvue Inc. (NYSE:KVUE) by 11.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 86,163 shares of the company’s stock after selling 11,291 shares during the period. Northeast Investment Management’s holdings in Kenvue were worth $1,840,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Grove Bank & Trust increased its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue in the 4th quarter valued at about $29,000. Riverview Trust Co bought a new stake in shares of Kenvue during the 3rd quarter valued at about $30,000. Fortitude Family Office LLC raised its stake in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares during the period. Finally, Ashton Thomas Securities LLC bought a new position in Kenvue in the third quarter worth about $35,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

KVUE opened at $20.23 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $38.79 billion, a PE ratio of 38.17, a P/E/G ratio of 2.16 and a beta of 1.45. The business has a fifty day simple moving average of $21.54 and a 200-day simple moving average of $21.95. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts predict that Kenvue Inc. will post 1.05 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.05%. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $26.00 in a report on Monday, January 6th. Barclays dropped their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. UBS Group dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday. Finally, Citigroup cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.